GSI (Complera emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg)

Generic Name: emtricitabine/rilpivirine/tenofovir

Pill imprint GSI has been identified as Complera emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg.

Complera is used in the treatment of hiv infection and belongs to the drug class antiviral combinations. There is no proven risk in humans during pregnancy. Complera emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg is not a controlled substance under the Controlled Substance Act (CSA).

Complera

Generic Name:

emtricitabine/rilpivirine/tenofovir

Imprint:

GSI

Strength:

emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg

Color:

Pink

Shape:

Capsule-shape

Availability:

Prescription only

Drug Class:

Antiviral combinations

Pregnancy Category:

B - No proven risk in humans

CSA Schedule:

Not a controlled drug

Manufacturer:

Gilead Sciences, Inc.

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.